Spots Global Cancer Trial Database for dasatinib
Every month we try and update this database with for dasatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia | NCT02689440 | Chronic Phase C... Philadelphia Ch... | Dasatinib Laboratory Biom... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib | NCT02733445 | Chronic Myeloid... | dasatinib nilotinib | 18 Years - | Bristol-Myers Squibb | |
| Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies | NCT03414450 | Ph+ Acute Lymph... Ph- Acute Lymph... Chronic Myeloid... Chronic Myeloid... | ETC-1907206 dasatinib | 18 Years - | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | |
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | NCT03041701 | Rhabdomyosarcom... Rhabdomyosarcom... Rhabdomyosarcom... | Dasatinib Dasatinib Ganitumab | 2 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | NCT00671788 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Dasatinib Laboratory Biom... | 18 Years - | GOG Foundation | |
| Frontline Asciminib Combination in Chronic Phase CML | NCT03906292 | Chronic Myeloid... | Imatinib Nilotinib 300 m... Dasatinib Asciminib | 18 Years - | University of Jena | |
| Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer | NCT00385580 | Prostate Cancer | dasatinib dasatinib | 18 Years - | Bristol-Myers Squibb | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | NCT00423735 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | Dasatinib Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer | NCT00903006 | Breast Cancer | Fulvestrant MK-0646 Dasatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia | NCT00852566 | Chronic Myeloid... | Imatinib Dasatinib | 18 Years - | Norwegian University of Science and Technology | |
| Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer | NCT00504153 | Recurrent Colon... Recurrent Recta... Stage IV Colon ... Stage IV Rectal... | dasatinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Dasatinib, Androgen Deprivation Therapy and Radiation | NCT01826838 | Prostate Cancer | Dasatinib | 18 Years - | Brown University | |
| Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT01238211 | Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Core Binding Fa... Secondary Acute... Therapy-Related... | Cytarabine Dasatinib Daunorubicin Hy... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | NCT00481247 | Myeloid Leukemi... | Dasatinib Imatinib | 18 Years - | Bristol-Myers Squibb | |
| Ph I Dasatinib + Erlotinib in Recurrent MG | NCT00609999 | Glioblastoma Gliosarcoma | Erlotinib and D... | 18 Years - | Duke University | |
| Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan | NCT01464411 | Leukemia, Myelo... Myelogenous Leu... | 20 Months - | Kanto CML Study Group | ||
| Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients | NCT00817531 | Breast Cancer | Dasatinib | 18 Years - 80 Years | Baylor Breast Care Center | |
| Phase II Dasatinib Study in Advanced Breast Cancer | NCT00546104 | Advanced Breast... | Dasatinib | 18 Years - | Duke University | |
| Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | NCT02709083 | Chronic Myeloge... Chronic Myeloid... Leukemia | Dasatinib Imatinib Mesyla... Nilotinib | 17 Years - | Emory University | |
| A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) | NCT01077544 | Chronic Myeloid... Acute Lymphobla... | Nilotinib | 1 Year - 17 Years | Novartis | |
| Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients | NCT02690922 | ph+ Acute Lymph... | Dasatinib prednisone dexamethasone methotrexate | 18 Years - | Tongji Hospital | |
| Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery | NCT00835679 | Liver Metastase... Mucinous Adenoc... Mucinous Adenoc... Recurrent Colon... Recurrent Recta... Signet Ring Ade... Signet Ring Ade... Stage IV Colon ... Stage IV Rectal... | cetuximab dasatinib therapeutic con... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) | NCT00500006 | Chronic Myeloge... Leukemia, Lymph... | MK0457 dasatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC | NCT00787267 | Non Small Cell ... | Dasatinib | 18 Years - | Duke University | |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | NCT01999985 | Lung Cancer Non-small Cell ... | Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib | NCT01593254 | Chronic Phase C... | Imatinib Dasatinib | 18 Years - | Bristol-Myers Squibb | |
| Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial | NCT01627132 | Chronic Myeloid... | Dasatinib | 15 Years - | Shimousa Hematology Study Group | |
| Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00507767 | Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer | dasatinib pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma | NCT00429949 | Relapsed, Refra... | Dasatinib | 18 Years - | Washington University School of Medicine | |
| Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma | NCT00560352 | Multiple Myelom... | Dasatinib Bortezomib Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors | NCT01751425 | Chronic Myeloge... Chronic Myeloge... Minimal Residua... Philadelphia Ch... | Dasatinib Imatinib Mesyla... Nilotinib Ruxolitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia | NCT02113319 | Acute Myelogeno... | dasatinib | 18 Years - 60 Years | University Hospital, Angers | |
| Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | NCT00826449 | Lung Cancer Non-Small Cell ... | Dasatinib Erlotinib | 16 Years - | M.D. Anderson Cancer Center | |
| Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia | NCT05993949 | Lymphoblastic L... | Dasatinib | 18 Years - | Stanford University | |
| Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan | NCT00337454 | Chronic Myeloge... | Dasatinib Dasatinib Dasatinib Dasatinib Dasatinib Dasatinib | 20 Years - 75 Years | Bristol-Myers Squibb | |
| BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia | NCT00103701 | Leukemia, Myelo... Leukemia, Lymph... | Dasatinib | 14 Years - | Bristol-Myers Squibb | |
| Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | NCT01256398 | Acute Lymphobla... Adult B Acute L... | Alemtuzumab Allogeneic Hema... Autologous Hema... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Etoposide Phosp... Filgrastim Fludarabine Pho... In Vitro-Treate... Laboratory Biom... Leucovorin Calc... Melphalan Mercaptopurine Methotrexate Pegfilgrastim Pharmacological... Tacrolimus Vincristine Sul... | 18 Years - | National Cancer Institute (NCI) | |
| Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00982488 | Leukemia | Dasatinib Imatinib | 18 Years - | Bristol-Myers Squibb | |
| Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia | NCT01460160 | Leukemia, Pedia... | Dasatinib | 1 Year - 17 Years | Bristol-Myers Squibb | |
| Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) | NCT00364286 | Leukemia Lymphoma | Dasatinib (BMS-... | - | M.D. Anderson Cancer Center | |
| Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) | NCT01724879 | Philadelphia Po... | Dasatinib | 18 Years - 55 Years | Goethe University | |
| Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | NCT01234935 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... | dasatinib gemcitabine hyd... laboratory biom... mutation analys... nucleic acid se... immunohistochem... | 18 Years - | Translational Oncology Research International | |
| Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | NCT00570700 | Hormone-refract... Adenocarcinoma ... Hormone-resista... Prostate Cancer Recurrent Prost... | Dasatinib | 18 Years - | University of California, Irvine | |
| Study of Erlotinib in Combination With Dasatinib | NCT00895128 | Advanced Cancer | Erlotinib Hydro... Dasatinib | 18 Years - | M.D. Anderson Cancer Center | |
| KRT-232 and TKI Study in Chronic Myeloid Leukemia | NCT04835584 | Chronic Myeloid... | KRT-232 Dasatinib Nilotinib | 18 Years - | Kartos Therapeutics, Inc. | |
| Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | NCT03625388 | Chronic Myeloge... | Dasatinib | 18 Years - | Hikma Pharmaceuticals LLC | |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | NCT02883049 | B Acute Lymphob... B Acute Lymphob... Central Nervous... Testicular Leuk... | Clofarabine Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Etoposide Hydrocortisone ... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Prednisone Radiation Thera... Thioguanine Vincristine Sul... | 1 Year - 31 Years | National Cancer Institute (NCI) | |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma | NCT00436605 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | dasatinib | 18 Years - | National Cancer Institute (NCI) | |
| Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer | NCT00903006 | Breast Cancer | Fulvestrant MK-0646 Dasatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | NCT03041701 | Rhabdomyosarcom... Rhabdomyosarcom... Rhabdomyosarcom... | Dasatinib Dasatinib Ganitumab | 2 Years - | National Institutes of Health Clinical Center (CC) | |
| Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction | NCT04925648 | Metastatic Pros... | Dasatinib Darolutamide | 18 Years - | St Vincent's Hospital, Sydney | |
| Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease | NCT03844360 | Hematological N... | Bortezomib Eltrombopag Imatinib dasatinib Pegaspargase Anti-Infective ... PEGylated Recom... | 1 Day - 18 Years | Shandong University | |
| Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00101595 | Chronic Myeloid... Leukemia, Lymph... | Dasatinib | 18 Years - | Bristol-Myers Squibb | |
| Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia | NCT01725204 | Leukemia, Myelo... | Dasatinib + Peg... | 18 Years - 70 Years | Norwegian University of Science and Technology | |
| Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL | NCT03564470 | Leukemia Leukemia, Acute Leukemia, Lymph... Leukemia, B-cel... | Chidamide Dasatinib | 14 Years - 55 Years | Nanfang Hospital, Southern Medical University | |
| Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial | NCT01887561 | Myelogenous Leu... | dasatinib | 15 Years - | Kanto CML Study Group | |
| Gemcitabine and Dasatinib in Advanced Solid Tumors | NCT00429234 | Advanced Cancer Solid Tumors | Dasatinib Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia | NCT02888990 | Leukemia, Lymph... | Dasatinib | 55 Years - | Versailles Hospital | |
| Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia | NCT01460693 | Myeloid Leukemi... | Imatinib Dasatinib | 18 Years - | Newcastle University | |
| Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia | NCT01310010 | Leukemia, Lymph... | dasatinib | 18 Years - | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | |
| Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT02819804 | B Acute Lymphob... Recurrent Adult... Recurrent Child... Refractory Adul... Refractory Chil... | Dasatinib Laboratory Biom... Nivolumab Pharmacological... | 18 Years - | Northwestern University | |
| Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery | NCT00662636 | Unspecified Adu... | dasatinib lapatinib ditos... pharmacological... laboratory biom... | 18 Years - | Mayo Clinic | |
| Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease | NCT03516279 | Chronic Phase C... Minimal Residua... | Dasatinib Imatinib Mesyla... Laboratory Biom... Nilotinib Pembrolizumab | 18 Years - | Eastern Cooperative Oncology Group | |
| Pilot Trial for Treatment of Recurrent Glioblastoma | NCT05432518 | Glioblastoma Recurrent Disea... Recurrent Gliob... | Afatinib Dasatinib Palbociclib Everolimus Olaparib | 18 Years - | AHS Cancer Control Alberta | |
| Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment | NCT03573596 | CML, Relapsed | Dasatinib | 18 Years - | Amsterdam UMC, location VUmc | |
| Phase II Dasatinib Study in Advanced Breast Cancer | NCT00546104 | Advanced Breast... | Dasatinib | 18 Years - | Duke University | |
| Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib | NCT00570401 | Lung Cancer | dasatinib | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) | NCT04578847 | Chronic Myeloid... Chronic Myeloid... BCR-ABL Positiv... | Imatinib Nilotinib Dasatinib Bosutinib | 18 Years - | National Research Center for Hematology, Russia | |
| Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | NCT00872976 | Chronic Lymphoc... | Dasatinib Combination of ... Dasatinib Combination of ... | 18 Years - | Bristol-Myers Squibb | |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | NCT02883049 | B Acute Lymphob... B Acute Lymphob... Central Nervous... Testicular Leuk... | Clofarabine Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Etoposide Hydrocortisone ... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Prednisone Radiation Thera... Thioguanine Vincristine Sul... | 1 Year - 31 Years | National Cancer Institute (NCI) | |
| Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia | NCT01725204 | Leukemia, Myelo... | Dasatinib + Peg... | 18 Years - 70 Years | Norwegian University of Science and Technology | |
| Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate | NCT01426334 | Accelerated Pha... Chronic Myeloge... Chronic Phase C... Relapsing Chron... | dasatinib diagnostic labo... pharmacological... cyclosporine | 18 Years - | National Cancer Institute (NCI) | |
| Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT02819804 | B Acute Lymphob... Recurrent Adult... Recurrent Child... Refractory Adul... Refractory Chil... | Dasatinib Laboratory Biom... Nivolumab Pharmacological... | 18 Years - | Northwestern University | |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | NCT04872790 | B Acute Lymphob... B Acute Lymphob... Mixed Phenotype... Recurrent B Acu... Recurrent Mixed... | Dasatinib Methotrexate Prednisone Rituximab Venetoclax Blinatumomab Bone Marrow Asp... Lumbar Puncture Biospecimen Col... | 18 Years - | OHSU Knight Cancer Institute | |
| Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00507767 | Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer | dasatinib pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response | NCT01850004 | Chronic Phase C... | Dasatinib | 18 Years - | Bristol-Myers Squibb | |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | NCT05286528 | Chronic Myeloid... | Bosutinib Imatinib Nilotinib Dasatinib Ponatinib | - | Pfizer | |
| A Phase I/II Study of Dasatinib and Dacarbazine | NCT00597038 | Metastatic Mela... | Dasatinib and D... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT01685125 | Hormone-resista... Recurrent Prost... Stage IV Prosta... | abiraterone ace... dasatinib prednisone | 18 Years - | University of Southern California |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
